Human EGFR Knockout Cell Line-T47D

The epidermal growth factor receptor (EGFR) gene is a key component in a complex network of cellular processes, particularly those related to cell growth, proliferation, and differentiation. EGFR is a transmembrane protein that, when bound to its specific ligand, undergoes dimerization and autophosphorylation, initiating a cascade of downstream signaling pathways. These pathways include the Ras-Raf-MEK-ERK pathway, the PI3K-AKT pathway, and the JAK-STAT pathway, which together promote a variety of cellular responses.

EGFR gene mutations are strongly associated with several types of cancer, most notably non-small cell lung cancer (NSCLC). These mutations can lead to aberrant activation of the EGFR signaling pathway, resulting in uncontrolled cell division and tumor growth. In NSCLC, two major types of EGFR mutations are commonly observed: deletions in exon 19 and L858R point mutations in exon 21. In addition to lung cancer, EGFR variants have been associated with other malignancies such as glioblastoma, colorectal cancer, and head and neck cancer. In glioblastoma, EGFR amplification and the presence of the EGFRvIII variant promote aggressive tumor behavior and resistance to conventional therapies. Similarly, in colorectal cancer, EGFR overexpression is associated with a poor prognosis and has led to the development of monoclonal antibodies such as cetuximab and panitumumab, which target the extracellular domain of the receptor.